What is Viracta Therapeutics Price-to-Operating-Cash-Flow?
As of today (2024-06-16), Viracta Therapeutics's share price is €0.605.
Viracta Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.87. Hence, Viracta Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Viracta Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 4 years, Viracta Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 187.68. The lowest was 0.00. And the median was 0.00.
Viracta Therapeutics's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was €-0.18.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.87.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -33.50% per year.
During the past 4 years, Viracta Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -33.50% per year. The lowest was -33.50% per year. And the median was -33.50% per year.
Viracta Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Viracta Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viracta Therapeutics Price-to-Operating-Cash-Flow Chart
|
Viracta Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
- |
- |
- |
- |
|
Viracta Therapeutics Quarterly Data
|
|
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Viracta Therapeutics's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Viracta Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viracta Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Viracta Therapeutics's Price-to-Operating-Cash-Flow falls into.
Viracta Therapeutics Price-to-Operating-Cash-Flow Calculation
Viracta Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.605 | / | -0.867 |
| = | |
Viracta Therapeutics's Share Price of today is €0.605.
Viracta Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.87.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Viracta Therapeutics (STU:RYIS) Business Description
Traded in Other Exchanges
Address
2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.
Viracta Therapeutics (STU:RYIS) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:RYIS has been successfully added to your